Vaxart Days Sales Outstanding from 2010 to 2025

VXRT Stock  USD 0.45  0.01  1.11%   
Vaxart Days Sales Outstanding yearly trend continues to be comparatively stable with very little volatility. Days Sales Outstanding is likely to outpace its year average in 2025. From the period from 2010 to 2025, Vaxart Days Sales Outstanding quarterly data regression had r-value of  0.26 and coefficient of variation of  63.33. View All Fundamentals
 
Days Sales Outstanding  
First Reported
2010-12-31
Previous Quarter
152.21898955
Current Value
159.83
Quarterly Volatility
58.76494601
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vaxart financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxart's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.3 M, Interest Expense of 1.9 M or Total Revenue of 27.3 M, as well as many indicators such as Price To Sales Ratio of 44.3, Dividend Yield of 0.0 or PTB Ratio of 23.49. Vaxart financial statements analysis is a perfect complement when working with Vaxart Valuation or Volatility modules.
  
Check out the analysis of Vaxart Correlation against competitors.

Latest Vaxart's Days Sales Outstanding Growth Pattern

Below is the plot of the Days Sales Outstanding of Vaxart Inc over the last few years. It is Vaxart's Days Sales Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxart's overall financial position and show how it may be relating to other accounts over time.
Days Sales Outstanding10 Years Trend
Pretty Stable
   Days Sales Outstanding   
       Timeline  

Vaxart Days Sales Outstanding Regression Statistics

Arithmetic Mean92.80
Geometric Mean72.23
Coefficient Of Variation63.33
Mean Deviation51.98
Median99.35
Standard Deviation58.76
Sample Variance3,453
Range162
R-Value0.26
Mean Square Error3,444
R-Squared0.07
Significance0.33
Slope3.25
Total Sum of Squares51,800

Vaxart Days Sales Outstanding History

2025 159.83
2024 152.22
2023 148.79
2022 68.22
2021 29.05
2020 30.13
2019 133.94

About Vaxart Financial Statements

Vaxart shareholders use historical fundamental indicators, such as Days Sales Outstanding, to determine how well the company is positioned to perform in the future. Although Vaxart investors may analyze each financial statement separately, they are all interrelated. The changes in Vaxart's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vaxart's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Days Sales Outstanding 152.22  159.83 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.